Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – According to analysts at Statista, the global economic impact of artificial intelligence (AI) in healthcare was worth approximately $11 billion, but by 2030 it’s expected to reach $188 billion, representing an astronomic CAGR of 37%. Major players are starting to believe in AI’s healthcare potential, with Ark Invest’s founder, CEO, and CIO, Cathie Wood recently pointing to new research by Mass General Brigham, citing the discovery of cancer survival using facial photograph analysis, and stating health care is likely to be AI’s “most profound application”. As big tech players are staking ground in the space, at the junior and mid-tier level, several innovators are making big strides, with recent developments coming from Avant Technologies, Inc. (OTCQB: AVAI), Spectral AI, Inc. (NASDAQ: MDAI), Tempus AI, Inc. (NASDAQ: TEM), Verastem Oncology (NASDAQ: VSTM), and Zimmer Biomet Holdings, Inc. (NYSE: ZBH).
The article continued: Doctors are quite bullish on the newfound abilities coming from artificial intelligence (AI) in healthcare, according to a new report from Philip, however patients aren’t so sure yet. As per the survey of 63% of 200 healthcare professionals and only 48% of over 1,000 patients in the USA believe AI could be helpful for improving health outcomes. Recently private company Pathos AI secured $365 million in Series D financing to advance cancer drug development through AI.
Avant Technologies and Ainnova Explore Integrating Early Detection of Dementia into AI-Powered Preventative Screening Platform
Avant Technologies, Inc. (OTCQB: AVAI), in partnership with its JV partner Ainnova Tech, is positioning its Vision AI platform at the forefront of predictive healthcare, a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are exploring options to integrate the early detection of dementia into Ainnova’s proprietary, AI-powered platform technology, Vision AI.
“This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years,” said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., of the potential expansion of its technology portfolio. “Adding the early detection of dementia that this patented technology presents us, would go a long way to making us a leader in the industry of early disease detection.”
The addition would reinforce the Company’s mission of expanding AI-powered early detection and preventative health solutions across the globe.
Currently, the Company has identified a promising patented early disease detection technology specializing in the early detection of dementia and is exploring its options to either license the technology globally or potentially acquire the technology altogether. The patented technology combines AI algorithms and hardware based on a 5-minute blood test. Adding the early detection of dementia would expand the offerings in the Company’s technology portfolio and enhance the broader vision of the partnership between Avant and Ainnova.
The success of the Company’s preventative screening platform involves the deployment of an automated, low-cost retinal imaging device integrated with the Vision AI platform to deliver comprehensive preventive risk screening. Presently, from just two retinal images, blood pressure and some lab test information, the Company’s system uses 4 integrated algorithms to assess risks for: (i) cardiovascular disease (CVD), (ii) type 2 diabetes, (iii) liver fibrosis, and (iv) chronic kidney disease (CKD).
Prior to the dementia announcement, Avant and Ainnova announced they’re in advanced discussions to acquire or exclusively license a patented early disease detection technology that could significantly enhance its diagnostic capabilities. If finalized, the deal would allow Vision AI to generate clinical insights even in the absence of a complete patient dataset—unlocking earlier intervention opportunities and supporting a more proactive model of care.
“Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily,” said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC), said of AAC’s aim to continue to add to its portfolio. “We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.”
The potential acquisition supports Avant and Ainnova’s mission to deliver scalable preventive health tools by combining retinal imaging, vital sign monitoring, and AI. Vision AI already screens for chronic conditions like diabetes, cardiovascular disease, and kidney dysfunction. Now, the platform is advancing further—evaluating new technologies to detect diseases at a pre-symptomatic stage.
With four proprietary algorithms trained on 2.3 million clinical cases already integrated, adding this new IP could significantly enhance Vision AI’s ability to extract predictive insights from minimal patient data.
Avant is now in formal talks to acquire Ainnova outright, expanding on their partnership under the Ai-nova Acquisition Corp. (AAC). The move comes ahead of a key FDA pre-submission meeting in July and aims to streamline operations, strengthen regulatory positioning, and support a unified U.S. market strategy.
Vision AI is the core of the initiative—a non-invasive platform that combines retinal imaging, vital sign monitoring, and machine learning to detect early signs of chronic disease. It screens for diabetic retinopathy, cardiovascular conditions, liver and kidney disorders, and type 2 diabetes. Operated through the Ai-nova Acquisition Corp. (AAC), the joint venture holds global rights to the platform, which has shown over 90% sensitivity in early detection, according to NIH-cited research.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Spectral AI, Inc. (NASDAQ: MDAI) announced that its partners, RCSI SWaT Research Center and Connolly Hospital, earned top honors at the 2025 Education Awards for research involving the DeepView® System. The award-winning project applied real-time AI and multispectral imaging to diabetic foot ulcer care.
“This award-winning research by our partners at RCSI is a significant milestone in validating the clinical value of our DeepView® System,” said Jeremiah Sparks, Chief Commercialization Officer of Spectral AI. “The real-world data generated in Ireland is not only expanding the clinical evidence base for DeepView but also helping shape our strategy for commercialization.”
This recognition underscores the DeepView platform’s ability to guide faster, more accurate wound assessments. The clinical data generated supports Spectral AI’s commercialization efforts and bolsters its growing evidence base.
Tempus AI, Inc. (NASDAQ: TEM) is partnering with Verastem Oncology (NASDAQ: VSTM) to co-develop a CDx test for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC), a rare cancer with limited treatment options.
"We look forward to continuing to work with Verastem to pursue an unmet need for patients with LGSOC, who, until now, had very few treatment options," said Mike Yasiejko, Executive Vice President and General Manager, Genomics, at Tempus. "Our xT CDx assay is uniquely positioned to support this work."
Tempus provided confirmatory testing during Verastem’s Phase 2 RAMP-201 trial, which helped secure FDA accelerated approval for a new drug combination. Their xT CDx assay is now being evaluated as an investigational tool in a Phase 3 trial to assess KRAS mutation status prospectively.
"Collaborating with Tempus to evaluate KRAS mutation status using the xT assay was an important component of the RAMP-201 clinical trial," said John Hayslip, MD, Chief Medical Officer of Verastem Oncology. "Continuing our collaboration to fully develop a CDx assay is part of our post-marketing commitment to the FDA for our recent accelerated approval of avutometinib plus defactinib and is a critical step in bringing targeted therapies to patients with recurrent KRAS-mutant LGSOC."
This collaboration represents a major step toward targeted precision therapy for hard-to-treat ovarian cancer.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) reported Q1 2025 net sales of $1.909 billion, reflecting steady growth and continued execution of its innovation agenda. The company is leveraging AI, digital tools, and surgical robotics to modernize orthopedic care and improve clinical outcomes.
"We are proud of our team's continued execution and performance to start the year, as we delivered solid first quarter results and advanced our bold innovation agenda," said Ivan Tornos, President and CEO of Zimmer Biomet. "The recently completed acquisition of Paragon 28 is another bold step toward our innovation and diversification ambitions, expanding our S.E.T. business with leading technologies and a dedicated commercial channel in the high-growth foot and ankle segment."
Its recent debut of ZBX™ for ambulatory centers and the integration of Paragon 28 support Zimmer Biomet’s push into high-growth, tech-enabled healthcare segments.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
Baystreet.ca
[email protected]
(250) 999-4849
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
